A method and system for evaluating and analyzing blood test results
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- ZHUJIANG HOSPITAL OF SOUTHERN MEDICAL UNIVERSITY
- Filing Date
- 2026-04-22
- Publication Date
- 2026-07-14
Smart Images
Figure CN122392958A_ABST
Abstract
Description
Technical Field
[0001] This invention relates to the field of information technology, and in particular to a method and system for evaluating and analyzing blood test results. Background Technology
[0002] In the field of clinical blood testing, especially in the precise determination of trace substances such as tumor markers, cross-contamination between samples directly affects the reliability of test results and the accuracy of disease screening. With the widespread use of fully automated biochemical analyzers in hospital laboratories, continuous testing of large batches of samples has become the norm. Ensuring that adjacent samples do not interfere with each other has become a crucial aspect of guaranteeing diagnostic quality. Most existing rinsing strategies employ a uniform approach with fixed parameters, using the same number of rinses, duration, and volume of fluid for all samples. This approach is generally effective when processing ordinary samples, but it reveals significant shortcomings when dealing with serum samples of different properties. Particularly when there are large differences in total protein concentration among samples, the rinsing effect shows significant inconsistency. While conventional long-duration single rinses may seem to clean thoroughly, their ability to remove the adsorbed layer remaining on the needle wall from high-protein samples is limited, making the problem more insidious and persistent.
[0003] The core technical challenge lies in the strong adhesion and slow release characteristics of the adsorption layer formed between the inner surface of the needle wall and the high-protein serum. This adsorption layer is difficult to completely destroy and replace under standard rinsing conditions. If the preceding sample is high-protein serum, trace amounts of protein and adsorbed analytes will continuously desorb from the needle wall during subsequent sample injections. This slow release process highly conflicts with the low-concentration characteristics of tumor marker detection, as tumor markers are often at the ng / mL or even pg / mL level. The release of even trace amounts of residue is sufficient to cause falsely elevated test values.
[0004] For example, in a continuous testing process, if the previous sample has a high total protein concentration and contains a certain biomarker, the instrument readings of subsequent patient samples with low protein and low concentrations may be raised to near or above the clinical threshold, even if the actual concentration value is very low. As a result, doctors may misjudge the results as positive and arrange unnecessary retests or further examinations.
[0005] Therefore, how to effectively identify the residual interference risk of preceding high-protein samples to subsequent tumor marker detection during continuous detection in a fully automated analyzer, and how to accurately control and compensate for this low-level cross-contamination caused by protein adsorption-slow release without sacrificing detection throughput, has become a key issue in ensuring the authenticity and reliability of tumor screening and monitoring results. Summary of the Invention
[0006] This invention provides a method for evaluating and analyzing blood test results, comprising:
[0007] The total protein concentration of the preceding samples was collected, and the total protein content level was detected by the built-in detection unit of the biochemical analyzer. The risk level of the preceding samples was determined based on the total protein content level.
[0008] Based on the risk level of the preceding sample, a pre-established flushing plan comparison table is queried, and the flushing execution plan corresponding to the risk level is extracted from the flushing plan comparison table;
[0009] Identify the detection item type of the subsequent sample, analyze the combination relationship between the risk level of the preceding sample and the detection item type of the subsequent sample, and when the preceding sample is of high protein level and the subsequent sample is a tumor marker detection item, mark it as a preceding high protein sample, execute the flushing execution plan, and record the flushing procedure execution record to obtain the ready state of the injection needle after cleaning.
[0010] Based on the cleaned and ready state of the injection needle, the original detection values of tumor markers in the subsequent samples are detected, and the number of intervals between the subsequent samples and the preceding high-protein samples is recorded to obtain the initial tumor marker concentration and the number of sample intervals in the subsequent samples.
[0011] The residual interference coefficient is queried based on the risk level of the preceding sample and the number of digits of the sample interval. The initial tumor marker concentration is then compensated based on the residual interference coefficient to obtain the adjusted tumor marker concentration.
[0012] The adjusted tumor marker concentration is compared with a preset false elevation detection threshold. When the concentration exceeds the false elevation detection threshold, it is marked as a residual sustained-release interference indicator. At the same time, the adjusted tumor marker concentration is compared with a preset re-examination threshold to obtain the result of the correction re-examination indication determination.
[0013] The detection results with residual slow-release interference indicators are associated with the rinsing procedure execution record, and the results are displayed on the biochemical analyzer interface based on the correction and review criteria.
[0014] Furthermore, the total protein concentration of the preceding samples is detected by the built-in detection unit of the biochemical analyzer. Based on the total protein content level, the preceding samples are classified into low-protein, medium-protein, or high-protein grades to obtain the risk level of the preceding samples, including:
[0015] The total protein concentration of the preceding sample is collected by the built-in detection unit of the biochemical analyzer. The detection unit detects the absorbance value, and the total protein concentration of the preceding sample is calculated based on the correspondence between the absorbance value and the protein concentration.
[0016] The total protein concentration detection value is compared with a pre-established protein content level boundary threshold, which includes an upper limit for low protein and a lower limit for high protein. Based on the comparison result, the protein content level of the preceding sample is determined to be low protein content, medium protein content, or high protein content.
[0017] Based on the protein content level determination result, the preceding sample is divided into low protein level, medium protein level or high protein level, and the corresponding risk level identification code is written into the biochemical analyzer to obtain the risk level of the preceding sample.
[0018] Furthermore, the step of querying a pre-established flushing plan comparison table based on the risk level of the preceding sample, and extracting the flushing execution plan corresponding to the risk level from the flushing plan comparison table, includes:
[0019] Using the risk level of the preceding sample as an index, the flushing plan comparison table is queried to obtain the parameter record row corresponding to the risk level;
[0020] Extract the number of flushing cycles, the duration of each flush, and the amount of flushing fluid used from the parameter record line. Combine and encapsulate the extracted number of flushing cycles, the duration of each flush, and the amount of flushing fluid used to obtain a flushing execution plan for the current risk level.
[0021] Furthermore, the process involves identifying the detection type of subsequent samples, analyzing the combination relationship between the risk level of the preceding samples and the detection type of the subsequent samples, and when the preceding sample is of high protein level and the subsequent sample is a tumor marker detection item, executing the flushing procedure and recording the flushing execution record to obtain a cleaned and ready-to-use state for the injection needle, including:
[0022] Obtain the test application form for the subsequent sample, read the test item code from the test application form, match the test item code with the pre-established project code and project type mapping table, determine whether the test item type of the subsequent sample is a tumor marker test item, and obtain the test item type determination result;
[0023] The detection item type determination result is combined and matched with the risk level of the preceding sample. When the preceding sample is of high protein level and the subsequent sample is a tumor marker detection item, a short-time high-frequency flushing mode is triggered. The number of flushing times and the duration of a single flushing are extracted from the flushing execution plan to obtain the execution parameters of the short-time high-frequency flushing mode.
[0024] According to the execution parameters, the injection needle drive unit sends a rinsing command. The injection needle drive unit controls the injection needle to reciprocate between the rinsing liquid container and the waste liquid tank according to the number of rinsing operations. Through multiple rapid replacement operations, residual components on the inner surface of the needle wall are removed, and a cleaned injection needle is obtained.
[0025] After the injection needle is cleaned, a rinsing procedure execution record is written into the rinsing log. The rinsing procedure execution record includes the preceding sample number, risk level, number of rinsings, rinsing duration, and rinsing completion timestamp. At the same time, the injection needle status is updated to ready.
[0026] Furthermore, based on the cleaned and ready state of the injection needle, the original detection values of tumor markers in the subsequent samples are detected, and the number of intervals between the subsequent samples and the preceding high-protein samples is recorded to obtain the initial tumor marker concentration and sample interval number of the subsequent samples, including:
[0027] When the injection needle is in the ready state, a sample aspiration command is sent to the injection needle drive unit. The injection needle moves to the subsequent sample container and aspirates the serum sample before releasing it into the reaction cup, thus completing the injection.
[0028] The subsequent samples were subjected to tumor marker detection by the biochemical analyzer detection unit, and the chemiluminescence signal was collected and converted into the raw detection value.
[0029] The initial tumor marker concentration is calculated based on the original detection value. At the same time, the position number difference between the subsequent sample and the preceding high-protein sample is obtained from the sample queue to obtain the sample interval number.
[0030] The initial tumor marker concentration is associated with the number of sample intervals and stored.
[0031] Furthermore, the step of querying the residual interference coefficient based on the risk level of the preceding sample and the number of digits of the sample interval, and compensating the initial tumor marker concentration based on the residual interference coefficient to obtain the adjusted tumor marker concentration includes:
[0032] Using the risk level of the preceding sample and the number of digits in the sample interval as indexes, a lookup table of residual interference coefficients is established in advance to obtain the residual interference coefficient corresponding to the current risk level and the number of digits in the sample interval.
[0033] Obtain the baseline interference concentration value from the pre-established interference parameter table, and subtract the product of the residual interference coefficient and the baseline interference concentration value from the initial tumor marker concentration to obtain the compensated concentration value.
[0034] The compensated concentration value is compared with a preset lower limit threshold. When the compensated concentration value is lower than the lower limit threshold, the adjusted tumor marker concentration is set as the lower limit threshold. When the compensated concentration value is not lower than the lower limit threshold, the compensated concentration value is used as the adjusted tumor marker concentration.
[0035] Furthermore, the adjusted tumor marker concentration is compared with a preset false elevation detection threshold. When the concentration exceeds the false elevation detection threshold, it is marked as residual sustained-release interference. Simultaneously, the adjusted tumor marker concentration is compared with a preset re-examination threshold to obtain the correction re-examination indication determination result, including:
[0036] Calculate the compensation difference between the initial tumor marker concentration and the adjusted tumor marker concentration, compare the compensation difference with the false elevation detection threshold, and write a residual sustained-release interference flag in the detection result record when the compensation difference exceeds the false elevation detection threshold.
[0037] The adjusted tumor marker concentration is compared with the re-examination threshold. If the adjusted tumor marker concentration exceeds the re-examination threshold, a re-examination is recommended. If the adjusted tumor marker concentration does not exceed the re-examination threshold, a re-examination is not required, thus obtaining the result of the corrected re-examination indication determination.
[0038] Furthermore, the step of associating the detection results with the residual slow-release interference marker with the rinsing procedure execution record, and presenting the results on the biochemical analyzer display interface based on the correction and review criteria, includes:
[0039] The test results with residual sustained-release interference labels are associated with the flushing procedure execution records by sample number. The adjusted tumor marker concentration, residual sustained-release interference labels, number of flushing times, flushing duration, and the results of the correction and re-examination criteria are integrated and written into the test evaluation record.
[0040] Based on the detection and evaluation records, the adjusted tumor marker concentrations, residual sustained-release interference indicators, and correction and re-examination indications are displayed on the biochemical analyzer interface.
[0041] On the other hand, the present invention provides a blood sample test result evaluation and analysis system, the system comprising:
[0042] The sample risk level classification module is used to collect the total protein concentration of the preceding sample, detect the total protein content level through the built-in detection unit of the biochemical analyzer, and classify the risk level of the preceding sample according to the total protein content level.
[0043] The flushing plan query module is used to query a pre-established flushing plan comparison table based on the risk level of the preceding sample, and extract the flushing execution plan corresponding to the risk level from the flushing plan comparison table;
[0044] The flushing mode control module is used to identify the detection item type of the subsequent sample, analyze the combination relationship between the risk level of the preceding sample and the detection item type of the subsequent sample, and when the preceding sample is of high protein level and the subsequent sample is a tumor marker detection item, it is marked as a preceding high protein sample, the flushing execution plan is executed, and the flushing program execution record is recorded to obtain the ready state of the injection needle after cleaning.
[0045] The sample injection and detection execution module is used to detect the original detection value of tumor markers in the subsequent sample based on the ready state of the cleaned injection needle, and simultaneously record the number of intervals between the subsequent sample and the preceding high-protein sample to obtain the initial tumor marker concentration and sample interval number of the subsequent sample.
[0046] The concentration compensation module is used to query the residual interference coefficient based on the risk level of the preceding sample and the number of digits of the sample interval, and to compensate the initial tumor marker concentration based on the residual interference coefficient to obtain the adjusted tumor marker concentration.
[0047] The false elevation assessment module is used to compare the adjusted tumor marker concentration with a preset false elevation identification threshold. When the false elevation identification threshold is exceeded, it is marked as a residual sustained-release interference indicator. At the same time, the adjusted tumor marker concentration is compared with a preset re-examination threshold to obtain the result of the correction re-examination indication determination.
[0048] The results integration and presentation module is used to associate the detection results with the residual slow-release interference indicator with the flushing procedure execution record, and present the results on the biochemical analyzer display interface according to the correction and review criteria.
[0049] The technical solutions provided by the embodiments of the present invention may include the following beneficial effects:
[0050] This invention discloses a method for evaluating and analyzing blood sample test results. Addressing the critical issue that high-protein sample residue can easily lead to false increases in subsequent tumor marker detection, the method categorizes and assesses the total protein concentration of preceding samples, dynamically generating an appropriate risk-level flushing plan. When a tumor marker test is performed following a high-protein preceding sample, a short-term, high-frequency flushing mode is intelligently triggered to effectively remove residual components from the injection needle wall. Simultaneously, a residual interference coefficient is introduced to precisely compensate the initial test value based on the sample interval, resulting in an adjusted tumor marker concentration. This is then combined with a false increase identification threshold and a retest threshold for comprehensive judgment. Finally, results with residual slow-release interference are identified, recorded, integrated, and clearly presented on the display interface. This invention strengthens the targeted nature of the flushing process from the source, quantitatively compensates for residual interference, automatically identifies false increases, and provides retest indications, significantly reducing the risk of false positives in tumor markers caused by cross-contamination of high-protein samples and improving the accuracy and reliability of biochemical analyzer test results. Attached Figure Description
[0051] Figure 1 This is a flowchart of a blood sample test result evaluation and analysis method according to the present invention.
[0052] Figure 2 This is a schematic diagram of a blood sample test result evaluation and analysis method according to the present invention.
[0053] Figure 3 This is another schematic diagram of a blood sample test result evaluation and analysis method according to the present invention.
[0054] Figure 4 This is a schematic diagram of the structure of a blood sample test result evaluation and analysis system according to the present invention. Detailed Implementation
[0055] To make the objectives, technical solutions, and advantages of this invention clearer, the invention will be described in detail below with reference to the accompanying drawings and specific embodiments.
[0056] like Figures 1-4 This embodiment of a blood sample test result evaluation and analysis method and system may specifically include:
[0057] Step S101: Collect the total protein concentration of the preceding sample, identify the total protein content level through the built-in detection unit of the biochemical analyzer, and classify the preceding sample into low protein level, medium protein level or high protein level according to the protein content level to obtain the risk level of the preceding sample.
[0058] The total protein concentration of the preceding sample was collected using the built-in detection unit of the biochemical analyzer. This unit employed the biuret colorimetric method to detect the absorbance of the colorimetric reaction between proteins and copper ions in the serum sample. The total protein concentration was calculated based on the linear correlation between absorbance and protein concentration, yielding the total protein concentration value of the preceding sample. This total protein concentration value was then compared to a pre-established protein content level threshold, which included an upper limit for low protein and a lower limit for high protein. If the total protein concentration was below the upper limit for low protein, it was determined to be at a low protein content level; if it was between the upper and lower limits, it was determined to be at a medium protein content level; and if it was above the lower limit, it was determined to be at a high protein content level. This yielded the protein content level determination result for the preceding sample. Based on the protein content level determination results, the preceding samples are classified into low protein level, medium protein level, or high protein level, and the corresponding risk level identification code is written into the biochemical analyzer to obtain the risk level of the preceding sample.
[0059] In one embodiment, the built-in detection unit of the biochemical analyzer uses the biuret colorimetric method to detect the total protein concentration of the preceding sample. The detection principle of the biuret colorimetric method is based on the complexation reaction between peptide bonds in protein molecules and alkaline copper ion solution, forming a purple-red complex. This complex has stable light absorption characteristics at a specific wavelength, and the absorbance value is directly proportional to the protein content in the sample.
[0060] Specifically, the detection unit mixes serum samples with biuret reagent in a reaction vessel, which is then placed in a thermostat to maintain a stable temperature. After the complexation reaction is complete, the spectrophotometer within the detection unit irradiates the reaction solution with monochromatic light of a specific wavelength. The photoelectric sensor receives the transmitted light signal and converts it into an electrical signal output. This electrical signal is then converted from analog to digital to obtain the absorbance value. The data processor within the detection unit, based on a pre-established standard curve of absorbance versus concentration, uses linear interpolation to convert the absorbance value into a total protein concentration value.
[0061] Specifically, the standard curve equation is C = k × A + b, where C is the total protein concentration (unit: g / L), A is the absorbance value (dimensionless), k is the slope coefficient, and b is the intercept. This standard curve is obtained by measuring protein standards of known concentrations under the same detection conditions, and the values of k and b are determined by least squares fitting.
[0062] It should be noted that the protein content level thresholds are preset based on the total protein concentration distribution characteristics of clinical serum samples. The upper limit of low protein and the lower limit of high protein divide the total protein concentration range into three intervals, corresponding to low protein content level, medium protein content level and high protein content level, respectively.
[0063] In one embodiment, the data processor compares the total protein concentration detection value with the upper limit of low protein levels. If the detection value is less than the upper limit, a low protein content level determination result is output. If the detection value is not less than the upper limit of low protein levels, it continues to compare with the lower limit of high protein levels. If the detection value is less than the lower limit of high protein levels, a medium protein content level determination result is output; if the detection value is not less than the lower limit of high protein levels, a high protein content level determination result is output. Based on the protein content level determination result, the biochemical analyzer writes a risk level identification code into the sample information record. Low protein level, medium protein level, and high protein level correspond to identification code values 1, 2, and 3, respectively. This identification code is associated with the sample number and stored. In subsequent testing processes, the system automatically reads this identification code. When it reads 2 or 3, it triggers an additional total protein verification or dilution adjustment. For example, identification code 2 automatically adds one verification, and identification code 3 automatically dilutes the sample by 2 times and retests to ensure the accuracy of the test results.
[0064] Step S102: Query the pre-established flushing plan comparison table according to the risk level, extract the flushing number, single flushing duration and flushing fluid volume of the corresponding level from the table, and obtain the flushing execution plan for the current risk level.
[0065] Based on the risk level of the preceding samples, an index query is performed in a pre-established flushing plan comparison table. This table uses risk level as the search keyword, and each risk level corresponds to a set of flushing parameter records. The corresponding parameter record row is obtained by matching the risk level. Three values—flushing frequency, single flushing duration, and flushing fluid volume—are extracted from these parameter record rows. These three extracted values are then combined and encapsulated to obtain the flushing execution plan for the current risk level.
[0066] The rinsing protocol reference table is pre-stored in the storage unit of the biochemical analyzer. The reference table adopts a key-value pair structure, with low protein grade, medium protein grade, and high protein grade as index keys. Each index key corresponds to a parameter record, which contains three fields: number of rinsings, duration of a single rinsing, and amount of rinsing solution used.
[0067] Specifically, when the biochemical analyzer receives the risk level of the preceding sample from the sample preprocessing module, the risk level of the preceding sample is determined based on the total protein concentration level of the sample. The risk level is used as the search condition in the reference table to perform a matching query, locate the corresponding parameter record row, and read the values of the three washing parameters stored in the record row.
[0068] For example, the rinsing execution plan is encapsulated in the form of a data structure, including a rinsing number field, a single rinsing duration field, and a rinsing fluid volume field. The values of the three fields are extracted and filled in from the parameter record row. The encapsulated rinsing execution plan serves as the input instruction for the needle cleaning control.
[0069] Step S103: Identify the detection item type of the subsequent sample, analyze the combination relationship between the risk level of the preceding sample and the detection item type of the subsequent sample. When the preceding sample is of high protein level and the subsequent sample is a tumor marker detection item, start the short-time high-frequency flushing mode according to the flushing execution plan. Perform multiple rapid replacement operations through the injection needle drive unit to remove residual components on the needle wall, record the flushing program execution record, and obtain the cleaned injection needle ready state.
[0070] Obtain the testing application form for the subsequent sample, read the testing item code from the application form, and perform a matching query against the pre-established and stored item code and item type mapping table in the biochemical analyzer database to determine whether the testing item type of the subsequent sample belongs to the tumor marker testing item, thus obtaining the testing item type determination result for the subsequent sample. Combine and match the testing item type determination result with the risk level of the preceding sample. If the preceding sample is of high protein level and the subsequent sample belongs to the tumor marker testing item, a short-time high-frequency flushing mode start signal is triggered. Extract the number of flushes and the duration of each flush from the flushing execution plan to obtain the execution parameters for the short-time high-frequency flushing mode. According to the execution parameters, a flushing command is sent to the injection needle drive unit. The injection needle drive unit controls the injection needle to reciprocate between the flushing solution container and the waste liquid tank according to the number of flushing cycles. During each cycle, the injection needle draws in the flushing solution and maintains it in the needle cavity for the duration of a single flush before discharging it. Through multiple rapid replacement operations, residual components on the inner surface of the needle wall are removed. This method is particularly suitable for combinations where high-protein samples are prone to forming stubborn residues and tumor marker detection is sensitive to trace amounts of contamination, ensuring the thorough elimination of potential cross-contamination risks and resulting in a clean injection needle. After the injection needle is cleaned, the biochemical analyzer writes a flushing procedure execution record to the preset flushing log. The flushing procedure execution record includes the previous sample number, risk level, number of flushing cycles, flushing duration, and flushing completion timestamp, and simultaneously updates the injection needle status indicator to the ready state.
[0071] In one implementation, the biochemical analyzer reads the test request form for subsequent samples from the sample queue. The test request form includes a sample number, patient information, and a test item code field. The test item code adopts a standardized coding rule, and each code uniquely corresponds to a test item.
[0072] Specifically, the pre-established project code and project type mapping table divides all testing projects into four categories: routine biochemical testing projects, tumor marker testing projects, hormone testing projects, and immune testing projects. Tumor marker testing projects include low-concentration, high-sensitivity indicators such as alpha-fetoprotein, carcinoembryonic antigen, and carbohydrate antigens.
[0073] It should be noted that the combination of risk level and test item type is designed based on the principle of cross-contamination sensitivity. High-protein serum samples form a protein adsorption layer on the inner wall of the injection needle, which has a slow release characteristic. When the subsequent test item is a tumor marker, because the clinically determined concentration of tumor markers is at an extremely low level, trace amounts of protein and adsorbed substances desorbed from the needle wall can significantly interfere with the test results. Therefore, the short-term high-frequency flushing mode is only triggered when the preceding sample is of high protein level and the subsequent sample is a tumor marker test item; other combinations will follow the standard flushing procedure.
[0074] In one embodiment, the combination matching determination is implemented through a logical AND operation. The biochemical analyzer reads the risk level identification code of the preceding sample and simultaneously obtains the determination result of the test item type of the subsequent sample. When both conditions are met, a trigger signal is output.
[0075] For example, the key difference between the short-time high-frequency rinsing mode and conventional rinsing lies in the use of multiple short-time rapid replacements instead of a single long-time immersion rinse. The number of rinses in the short-time high-frequency rinsing mode is 2-3 times that of conventional rinsing, and the duration of a single rinse is 1 / 3-1 / 2 of the duration of conventional rinsing. By increasing the replacement frequency and shortening the single residence time, a stronger turbulent scouring effect is formed in the needle cavity. The injection needle drive unit includes a stepper motor, a lead screw transmission mechanism, and a position sensor. After receiving the rinsing command, the stepper motor drives the lead screw to rotate, causing the injection needle to reciprocate between the rinsing solution container and the waste liquid tank in a vertical direction. During each downward movement, the tip of the injection needle is immersed in the rinsing solution container, and the injection pump generates negative pressure to draw the rinsing solution into the needle cavity. After the rinsing solution stays in the needle cavity for the duration of a single rinse, the injection needle moves upward to above the waste liquid tank, and the injection pump generates positive pressure to discharge the rinsing solution along with the residual components on the needle wall.
[0076] Understandably, rapid displacement operation creates a turbulent flushing effect in the needle cavity through repeated inhalation and exhalation. Compared with static soaking and rinsing, it can more effectively destroy the protein adsorption layer on the inner surface of the needle wall, allowing the proteins adsorbed on the needle wall and the analytes they carry to be discharged along with the rinsing solution.
[0077] Preferably, the amount of rinsing fluid used is based on a pre-set rinsing execution plan, which includes parameters such as the number of rinsings, the duration of each rinsing, and the amount of rinsing fluid used. This plan is precisely controlled by the syringe pump, ensuring that the volume of rinsing fluid drawn in each rinsing is consistent, and that the total amount used in multiple rinsings does not exceed the pre-set rinsing fluid quota for a single sample. Furthermore, after the injection needle has completed all rinsing, the biochemical analyzer creates a new record in the rinsing log database, recording the previous sample number to trace the source of contamination, the risk level to indicate the degree of contamination, the actual number of rinsings and the total duration to support quality verification, and a completion timestamp to ensure the integrity of the timeline.
[0078] In one possible implementation, the status identifier of the injection needle is stored in the status register of the biochemical analyzer. After the rinsing procedure is completed, the corresponding bit in the status register is set to the ready status value. The subsequent sample injection and detection procedure confirms that the injection needle has been cleaned by querying the status identifier before starting the sampling operation for subsequent samples.
[0079] Step S104: Based on the cleaned and ready state of the injection needle, the subsequent sample is injected for detection. The original detection values of tumor markers are collected by the biochemical analyzer detection unit. At the same time, the number of intervals between the subsequent sample and the preceding high-protein sample is recorded to obtain the initial tumor marker concentration and the number of sample intervals for the subsequent sample.
[0080] After confirming the needle's readiness, the biochemical analyzer sends a sampling command to the needle drive unit. The needle moves above the subsequent sample container and descends to a preset sampling depth. The injection pump generates negative pressure to draw serum from the subsequent sample into the needle chamber. After sampling, the needle moves to the reaction cup to release the serum sample, resulting in the completed subsequent sample. The biochemical analyzer's detection unit performs tumor marker detection on the completed subsequent sample. The detection unit uses chemiluminescence immunoassay to quantitatively measure tumor markers in the serum. A photomultiplier tube collects the chemiluminescence signal intensity and converts it into an electrical signal to obtain the raw detection value of the subsequent sample. Based on the raw detection value, the position number of the subsequent sample and the position number of the preceding high-protein sample are obtained from the sample queue. The position number is a preset unique sequence identifier for the sample in the queue. The position number of the subsequent sample is subtracted from the position number of the preceding high-protein sample to obtain the sample interval length between the subsequent and preceding high-protein samples. Based on the pre-established standard curve of luminescence intensity and concentration, the original detection value is converted into the initial tumor marker concentration, and the sample interval digits are associated with and stored with the initial tumor marker concentration. The initial tumor marker concentration field and the sample interval digits field are written into the detection result data record at the same time.
[0081] In one embodiment, before performing the sample injection operation, the biochemical analyzer reads the status flag value in the injection needle status register. When the status flag value is ready, it indicates that the injection needle has completed the previous rinsing procedure, there is no residual sample or rinsing fluid in the needle cavity, and it is ready to perform the next sample aspiration.
[0082] Specifically, after receiving the aspiration command, the injection needle drive unit drives the injection needle to move horizontally to directly above the subsequent sample container, and then descends vertically. The needle tip passes through the sealing membrane of the sample container and enters a preset depth position below the serum liquid surface. The injection pump starts the negative pressure aspiration action to draw the quantitative serum sample into the needle cavity.
[0083] It should be noted that the chemiluminescent immunoassay is a quantitative detection method that combines the specificity of an immune reaction with the high sensitivity of chemiluminescence detection. In a reaction vessel, a serum sample is mixed and incubated with magnetic microspheres coated with specific antibodies. Tumor marker antigens in the sample specifically bind to the capture antibodies on the surface of the magnetic microspheres, forming an antigen-antibody complex. Subsequently, a detection antibody labeled with acridinium ester luminescent agent is added, forming a double-antibody sandwich structure with the antigen already bound to the magnetic microspheres. After magnetic separation and washing to remove unbound free components, a pre-excitation solution and an excitation solution are sequentially injected into the reaction vessel. Acridinium ester undergoes an oxidation reaction in an alkaline hydrogen peroxide environment, releasing photons and generating a transient chemiluminescent signal.
[0084] In one embodiment, the photomultiplier tube is located directly above the detection window of the reaction cup. When the chemiluminescence reaction occurs, the photocathode of the photomultiplier tube receives the luminescence signal and converts the photons into photoelectrons. After being amplified by a cascade of multiple dynodes, a current signal proportional to the luminescence intensity is output at the anode. This current signal is converted into a digital signal by an analog-to-digital converter and output.
[0085] For example, the standard curve of luminescence intensity versus concentration is pre-established as follows: Tumor marker standard solutions of known concentrations are selected, with concentration gradients covering the detection range from low to high values. The standard solutions at each concentration gradient are measured according to the same detection procedure, and the luminescence intensity values corresponding to each concentration point are recorded. A standard curve is plotted with standard concentration as the abscissa and luminescence intensity as the ordinate. A four-parameter logistic regression fitting method is used to fit the discrete data points to the curve. The four-parameter logistic regression equation is: Where Y is the luminescence intensity, X is the tumor marker concentration, A is the minimum asymptotic value, D is the maximum asymptotic value, C is the inflection point concentration (the X value corresponding to the midpoint between A and D), and B is the slope factor. The concentration can be calculated from the luminescence intensity using an inverse function. The standard curve equation is stored in the biochemical analyzer's calibration database. Furthermore, the calculation of the sample interval digits is based on the position number of each sample in the sample queue. The sample queue is arranged in the order of loading, and each sample container has a unique position number on the sample rack. The biochemical analyzer retrieves the position number of the current subsequent sample from the sample information database, and simultaneously retrieves the position number of the most recent preceding sample marked as high protein level. The positive difference between the subsequent sample position number and the preceding high protein sample position number is the interval digit between the current sample and the preceding high protein sample.
[0086] Understandably, the number of sample intervals reflects the relative distance between subsequent samples and preceding high-protein samples in the detection sequence. The smaller the number of intervals, the closer the subsequent samples are to the high-protein samples, and the higher the risk of interference from the slow-release of the needle wall protein adsorption layer. The larger the number of intervals, the lower the risk of interference.
[0087] Preferably, the conversion process for the initial tumor marker concentration is as follows: Substitute the original detection value of the subsequent sample, i.e., the luminescence intensity value, into the pre-established standard curve equation, and calculate the concentration value corresponding to the luminescence intensity through the inverse function operation of the four-parameter logistic regression equation. This concentration value is the initial tumor marker concentration, and the unit is consistent with the concentration unit of the standard used when establishing the standard curve.
[0088] In one possible implementation, the biochemical analyzer establishes a correlation field in the test result data record, writes the initial tumor marker concentration and the number of sample intervals into the same data record, and establishes an index association with the sample number of subsequent samples, the test time, and the number of the preceding high-protein sample, so as to facilitate subsequent source tracing and interference assessment of the test results.
[0089] Step S105: Based on the risk level of the preceding samples and the number of digits in the sample interval, identify the residual interference coefficient, and compensate the initial tumor marker concentration according to the residual interference coefficient to obtain the adjusted tumor marker concentration.
[0090] Based on the risk level of the preceding samples and the number of digits in the sample interval, a two-dimensional index lookup is performed in a pre-established residual interference coefficient lookup table. This lookup table uses risk level as the row index and the number of digits in the sample interval as the column index, storing a residual interference coefficient value at each index intersection. This yields a residual interference coefficient matching the current risk level and the number of digits in the sample interval. The initial tumor marker concentration is then compensated based on this residual interference coefficient. A baseline interference concentration value is obtained from a pre-established interference parameter table. The initial tumor marker concentration is subtracted from the product of the residual interference coefficient and the baseline interference concentration value to obtain the compensated concentration value. This compensated concentration value is compared with a preset lower limit threshold. If the compensated concentration value is lower than the lower limit threshold, the adjusted tumor marker concentration is set as the lower limit threshold. If the compensated concentration value is not lower than the lower limit threshold, the compensated concentration value is used as the adjusted tumor marker concentration.
[0091] In one embodiment, the residual interference coefficient reference table is stored in the parameter database of the biochemical analyzer. The reference table adopts a matrix structure, with the row dimension corresponding to three risk levels: low protein level, medium protein level, and high protein level, and the column dimension corresponding to the sequence of sample interval digits from one to the preset maximum interval number.
[0092] It should be noted that the residual interference coefficient values at each position in the reference table were predetermined through experimental calibration. For each risk level, a standard serum sample of known concentration was used as the preceding sample. The luminescence intensity values of blank samples at different interval positions were collected. The detected residual signal values were converted into concentration values (Cr) using a standard curve. The residual interference coefficient was calculated using the formula: R(i,n) = Cr / Cb, where R(i,n) is the residual interference coefficient of the i-th risk level at the n-th interval position, Cr is the residual concentration detected at that position, and Cb is the baseline interference concentration. This coefficient reflects the slow release characteristic of proteins adsorbed on the needle wall surface. The coefficient values corresponding to high protein levels are generally higher than those of medium and low protein levels. Within the same risk level, the coefficient values decrease with increasing interval position, reflecting the slow-release decay characteristics of the needle wall protein adsorption layer.
[0093] Specifically, the biochemical analyzer locates the row position of the control table based on the risk level of the preceding samples, locates the column position of the control table based on the number of sample intervals, and reads the residual interference coefficient stored at the intersection of the row and column.
[0094] In one embodiment, the baseline interference concentration value is stored in an interference parameter table. This value represents the typical interference concentration caused by a high-protein grade sample in its immediate vicinity to subsequent samples, and is determined by averaging the values obtained from batch experiments. The specific formula for the compensation calculation is: Ca = C0 - R × Cb, where Ca is the adjusted tumor marker concentration (units consistent with C0), C0 is the initial tumor marker concentration, R is the residual interference coefficient (dimensionless, ranging from 0 to 1), and Cb is the baseline interference concentration value (units consistent with C0). This formula ensures that all dimensions are consistent, all being concentration units. Furthermore, after the compensation calculation is completed, the biochemical analyzer compares the compensated concentration value with a lower limit threshold. The lower limit threshold is set as the minimum detection limit of the tumor marker detection method. When the compensated value is lower than this threshold, the lower limit threshold is used instead as the adjusted tumor marker concentration output to avoid invalid concentration values below the sensitivity of the detection method.
[0095] Step S106: Evaluate whether the adjusted tumor marker concentration value exceeds the preset false elevation identification threshold. If it exceeds the threshold, it is identified as a false elevation and marked as a residual sustained-release interference marker. At the same time, the adjusted tumor marker concentration is compared with the preset re-examination threshold to obtain the correction re-examination indication judgment result.
[0096] The adjusted tumor marker concentration and the initial tumor marker concentration are obtained. The adjusted tumor marker concentration is subtracted from the initial tumor marker concentration to obtain a compensation difference. This compensation difference is compared with a preset false elevation detection threshold. If the compensation difference exceeds the false elevation detection threshold, the initial test result is determined to have a false elevation, resulting in a false elevation determination result. Based on the false elevation determination result, a residual sustained-release interference flag field is written into the test result data record. The residual sustained-release interference flag is used to mark that the initial test value of the sample is interfered with by residual components of the preceding high-protein sample, resulting in a test result record with a residual sustained-release interference flag. For the test result record with the residual sustained-release interference flag, the adjusted tumor marker concentration is compared with a preset retest threshold. If the adjusted tumor marker concentration exceeds the retest threshold, the result is a recommendation for retesting; if the adjusted tumor marker concentration does not exceed the retest threshold, the result is no retest required, resulting in a correction retest indication determination result.
[0097] In one implementation, the biochemical analyzer reads the initial tumor marker concentration and the adjusted tumor marker concentration from the test result data record, and calculates the compensation difference D = D0 - D a， Where D0 is the initial tumor marker concentration, D a The adjusted tumor marker concentrations reflect the degree of residual interference.
[0098] It should be noted that the false elevation detection threshold is preset based on the clinical diagnostic characteristics of tumor markers. False elevation detection threshold T f The calculation formula is: T f =α×T c T c This represents the clinical cutoff value for the tumor marker, where α is a coefficient factor, with a value ranging from 1.2 to 2.0 and a recommended value of 1.3 to 1.5. If the compensation difference D = C0 - Ca > T f If the initial tumor marker concentration is C0, and the adjusted tumor marker concentration is Ca, then it is considered a false elevation. When the compensation difference exceeds this threshold, it indicates that residual interfering components in the initial test value are sufficient to affect clinical judgment.
[0099] For example, for alpha-fetoprotein (AFP) testing, if the clinical threshold is a certain concentration level, the threshold for identifying false elevations can be set as a preset percentage of that threshold.
[0100] Specifically, when a false elevation is detected, the biochemical analyzer writes a residual sustained-release interference flag field into the sample's test result data record. This flag field is set to a flagged state to facilitate identification of cross-contamination interference during subsequent report review. Furthermore, the retest threshold is set independently of the false elevation detection threshold. The retest threshold is typically set to the clinical threshold value of the tumor marker or a value slightly below it. The biochemical analyzer compares the adjusted tumor marker concentration with the retest threshold to determine whether the compensated concentration remains within the clinically relevant range.
[0101] In one possible implementation, if the adjusted tumor marker concentration exceeds the re-examination threshold, the output of the corrected re-examination indication judgment result is "re-examination recommended," indicating that the concentration of the sample is still too high even after excluding residual interference; if the adjusted tumor marker concentration does not exceed the re-examination threshold, the output of the corrected re-examination indication judgment result is "no re-examination required," indicating that the abnormality of the initial test result is mainly caused by residual interference.
[0102] Step S107: The test results with residual slow-release interference markers are integrated with the rinsing procedure execution record, and the results are displayed on the biochemical analyzer interface according to the correction and re-examination criteria, thus completing the evaluation and analysis of the blood sample test results.
[0103] The test results record with the residual sustained-release interference label is associated and matched with the flushing procedure execution record by sample number. The adjusted tumor marker concentration, residual sustained-release interference label, number of flushes, flushing time, and correction and re-examination indications from both records are integrated and written into a single test evaluation report to obtain an integrated blood sample test evaluation report. Based on the integrated blood sample test evaluation report, the adjusted tumor marker concentration, residual sustained-release interference label status, and correction and re-examination indications are displayed on the biochemical analyzer interface to complete the evaluation and analysis of the blood sample test results.
[0104] In one implementation, the biochemical analyzer uses the sample number as the primary key to retrieve test result records with residual interference indicators in the test result database, and simultaneously retrieves the flushing procedure execution record corresponding to the previous sample associated with the sample number in the flushing log database. The two records are then linked and merged, wherein the previous sample is the sample injected before the current sample.
[0105] Specifically, the detection and evaluation report includes fields such as basic sample information, adjusted tumor marker concentration, initial tumor marker concentration, residual interference status, preceding high-protein sample number, number of washes, wash duration, and determination results of correction and re-examination criteria.
[0106] For example, the biochemical analyzer presents the test evaluation report in the form of a list or card on the display interface. When the residual slow-release interference indicator status is marked, the display interface will indicate the risk of cross-contamination interference in the sample in a prominent manner. When the result of the correction and re-examination indication judgment is to recommend re-examination, the display interface will simultaneously output re-examination prompt information, so as to facilitate the comprehensive evaluation of the blood sample test results by the laboratory personnel.
[0107] This invention provides a blood sample test result evaluation and analysis system, mainly comprising:
[0108] The sample risk level classification module is used to collect the total protein concentration of the preceding sample, identify the total protein content level through the built-in detection unit of the biochemical analyzer, and classify the preceding sample into low protein level, medium protein level or high protein level according to the protein content level to obtain the risk level of the preceding sample.
[0109] The flushing plan query module is used to query a pre-established flushing plan comparison table based on the risk level, extract the number of flushing times, single flushing duration and flushing fluid usage for the corresponding level from the table, and obtain the flushing execution plan for the current risk level.
[0110] The flushing mode control module is used to identify the detection item type of subsequent samples and analyze the combination relationship between the risk level of the preceding sample and the detection item type of the subsequent sample. When the preceding sample is of high protein level and the subsequent sample is a tumor marker detection item, the short-time high-frequency flushing mode is started according to the flushing execution plan. The needle drive unit performs multiple rapid replacement operations to remove residual components from the needle wall, records the flushing program execution record, and obtains the ready state of the cleaned needle.
[0111] The sample injection and detection execution module is used to perform sample injection and detection on subsequent samples based on the ready state of the cleaned injection needle. The original detection values of tumor markers are collected by the biochemical analyzer detection unit, and the number of intervals between subsequent samples and preceding high-protein samples are recorded to obtain the initial tumor marker concentration and sample interval number of subsequent samples.
[0112] The concentration compensation module is used to identify the residual interference coefficient based on the risk level of the preceding sample and the number of digits in the sample interval, and to compensate the initial tumor marker concentration based on the residual interference coefficient to obtain the adjusted tumor marker concentration.
[0113] The false elevation assessment module is used to assess whether the adjusted tumor marker concentration value exceeds the preset false elevation identification threshold. When it exceeds the threshold, it is identified as a false elevation and marked as a residual sustained-release interference. At the same time, the adjusted tumor marker concentration is compared with the preset re-examination threshold to obtain the result of the correction re-examination indication judgment.
[0114] The results integration and presentation module is used to integrate the test results with residual slow-release interference indicators and the flushing procedure execution record, and present the results on the biochemical analyzer display interface according to the correction and re-examination criteria, thus completing the evaluation and analysis of blood sample test results.
[0115] If the technical solution of this application involves personal information, the product using this technical solution has clearly informed the user of the personal information processing rules and obtained the user's voluntary consent before processing the personal information. If the technical solution of this application involves sensitive personal information, the product using this technical solution has obtained the user's separate consent before processing the sensitive personal information, and also meets the requirement of "express consent". For example, at personal information collection devices such as cameras, clear and prominent signs are set up to inform users that they have entered the scope of personal information collection and that personal information will be collected. If an individual voluntarily enters the collection scope, it is deemed that they have agreed to the collection of their personal information; or on the personal information processing device, the personal information processing rules are clearly informed through signs / information, and authorization is obtained through pop-up information or by asking the individual to upload their personal information; wherein, the personal information processing rules may include information such as the personal information processor, the purpose of personal information processing, the processing method, and the types of personal information processed.
[0116] The above embodiments are merely one of the preferred embodiments of the present invention and should not be used to limit the scope of protection of the present invention. Any modifications or refinements made to the main design concept and spirit of the present invention that are not of substantial significance, but solve the same technical problem as the present invention, should be included within the scope of protection of the present invention.
Claims
1. A method for evaluating and analyzing blood test results, characterized in that, include: The total protein concentration of the preceding samples was collected, and the total protein content level was detected by the built-in detection unit of the biochemical analyzer. The risk level of the preceding samples was determined based on the total protein content level. Based on the risk level of the preceding sample, a pre-established flushing plan comparison table is queried, and the flushing execution plan corresponding to the risk level is extracted from the flushing plan comparison table; Identify the detection item type of the subsequent sample, analyze the combination relationship between the risk level of the preceding sample and the detection item type of the subsequent sample, and when the preceding sample is of high protein level and the subsequent sample is a tumor marker detection item, mark it as a preceding high protein sample, execute the flushing execution plan, and record the flushing procedure execution record to obtain the ready state of the injection needle after cleaning. Based on the cleaned and ready state of the injection needle, the original detection values of tumor markers in the subsequent samples are detected, and the number of intervals between the subsequent samples and the preceding high-protein samples is recorded to obtain the initial tumor marker concentration and the number of sample intervals in the subsequent samples. The residual interference coefficient is queried based on the risk level of the preceding sample and the number of digits of the sample interval. The initial tumor marker concentration is then compensated based on the residual interference coefficient to obtain the adjusted tumor marker concentration. The adjusted tumor marker concentration is compared with a preset false elevation detection threshold. When the concentration exceeds the false elevation detection threshold, it is marked as a residual sustained-release interference indicator. At the same time, the adjusted tumor marker concentration is compared with a preset re-examination threshold to obtain the result of the correction re-examination indication determination. The detection results with residual slow-release interference indicators are associated with the rinsing procedure execution record, and the results are displayed on the biochemical analyzer interface based on the correction and review criteria.
2. The method for evaluating and analyzing blood test results according to claim 1, characterized in that, The total protein concentration of the preceding samples is detected by the built-in detection unit of a biochemical analyzer. Based on the total protein content level, the preceding samples are classified into low-protein, medium-protein, or high-protein grades to obtain the risk level of the preceding samples, including: The total protein concentration of the preceding sample is collected by the built-in detection unit of the biochemical analyzer. The detection unit detects the absorbance value, and the total protein concentration of the preceding sample is calculated based on the correspondence between the absorbance value and the protein concentration. The total protein concentration detection value is compared with a pre-established protein content level boundary threshold, which includes an upper limit for low protein and a lower limit for high protein. Based on the comparison result, the protein content level of the preceding sample is determined to be low protein content, medium protein content, or high protein content. Based on the protein content level determination result, the preceding sample is divided into low protein level, medium protein level or high protein level, and the corresponding risk level identification code is written into the biochemical analyzer to obtain the risk level of the preceding sample.
3. The method for evaluating and analyzing blood test results according to claim 1, characterized in that, The step of querying a pre-established flushing plan comparison table based on the risk level of the preceding sample, and extracting the flushing execution plan corresponding to the risk level from the flushing plan comparison table, includes: Using the risk level of the preceding sample as an index, the flushing plan comparison table is queried to obtain the parameter record row corresponding to the risk level; Extract the number of flushing cycles, the duration of each flush, and the amount of flushing fluid used from the parameter record line. Combine and encapsulate the extracted number of flushing cycles, the duration of each flush, and the amount of flushing fluid used to obtain a flushing execution plan for the current risk level.
4. The method for evaluating and analyzing blood test results according to claim 1, characterized in that, The process involves identifying the detection type of subsequent samples, analyzing the combination relationship between the risk level of the preceding samples and the detection type of the subsequent samples, and, when the preceding sample is of high protein level and the subsequent sample is a tumor marker detection item, executing the flushing procedure and recording the flushing execution record to obtain a cleaned and ready-to-use state for the injection needle, including: Obtain the test application form for the subsequent sample, read the test item code from the test application form, match the test item code with the pre-established project code and project type mapping table, determine whether the test item type of the subsequent sample is a tumor marker test item, and obtain the test item type determination result; The detection item type determination result is combined and matched with the risk level of the preceding sample. When the preceding sample is of high protein level and the subsequent sample is a tumor marker detection item, a short-time high-frequency flushing mode is triggered. The number of flushing times and the duration of a single flushing are extracted from the flushing execution plan to obtain the execution parameters of the short-time high-frequency flushing mode. According to the execution parameters, the injection needle drive unit sends a rinsing command. The injection needle drive unit controls the injection needle to reciprocate between the rinsing liquid container and the waste liquid tank according to the number of rinsing operations. Through multiple rapid replacement operations, residual components on the inner surface of the needle wall are removed, and a cleaned injection needle is obtained. After the injection needle is cleaned, a rinsing procedure execution record is written into the rinsing log. The rinsing procedure execution record includes the preceding sample number, risk level, number of rinsings, rinsing duration, and rinsing completion timestamp. At the same time, the injection needle status is updated to ready.
5. The method for evaluating and analyzing blood test results according to claim 1, characterized in that, Based on the cleaned and ready state of the injection needle, the raw detection values of tumor markers in the subsequent samples are detected, and the number of intervals between the subsequent samples and the preceding high-protein samples is recorded to obtain the initial tumor marker concentration and sample interval number of the subsequent samples, including: When the injection needle is in the ready state, a sample aspiration command is sent to the injection needle drive unit. The injection needle moves to the subsequent sample container and aspirates the serum sample before releasing it into the reaction cup, thus completing the injection. The subsequent samples were subjected to tumor marker detection by the biochemical analyzer detection unit, and the chemiluminescence signal was collected and converted into the raw detection value. The initial tumor marker concentration is calculated based on the original detection value. At the same time, the position number difference between the subsequent sample and the preceding high-protein sample is obtained from the sample queue to obtain the sample interval number. The initial tumor marker concentration is associated with the number of sample intervals and stored.
6. The method for evaluating and analyzing blood test results according to claim 1, characterized in that, The step of querying the residual interference coefficient based on the risk level of the preceding sample and the number of digits of the sample interval, and compensating the initial tumor marker concentration based on the residual interference coefficient to obtain the adjusted tumor marker concentration includes: Using the risk level of the preceding sample and the number of digits in the sample interval as indexes, a lookup table of residual interference coefficients is established in advance to obtain the residual interference coefficient corresponding to the current risk level and the number of digits in the sample interval. Obtain the baseline interference concentration value from the pre-established interference parameter table, and subtract the product of the residual interference coefficient and the baseline interference concentration value from the initial tumor marker concentration to obtain the compensated concentration value. The compensated concentration value is compared with a preset lower limit threshold. When the compensated concentration value is lower than the lower limit threshold, the adjusted tumor marker concentration is set as the lower limit threshold. When the compensated concentration value is not lower than the lower limit threshold, the compensated concentration value is used as the adjusted tumor marker concentration.
7. The method for evaluating and analyzing blood test results according to claim 1, characterized in that, The adjusted tumor marker concentration is compared with a preset false elevation detection threshold. When the concentration exceeds the false elevation detection threshold, it is marked as residual sustained-release interference. Simultaneously, the adjusted tumor marker concentration is compared with a preset re-examination threshold to obtain the correction and re-examination indication determination result, including: Calculate the compensation difference between the initial tumor marker concentration and the adjusted tumor marker concentration, compare the compensation difference with the false elevation detection threshold, and write a residual sustained-release interference flag in the detection result record when the compensation difference exceeds the false elevation detection threshold. The adjusted tumor marker concentration is compared with the re-examination threshold. If the adjusted tumor marker concentration exceeds the re-examination threshold, a re-examination is recommended. If the adjusted tumor marker concentration does not exceed the re-examination threshold, a re-examination is not required, thus obtaining the result of the corrected re-examination indication determination.
8. The method for evaluating and analyzing blood test results according to claim 1, characterized in that, The process of associating the detection results with residual slow-release interference markers with the rinsing procedure execution record, and presenting the results on the biochemical analyzer display interface based on the correction and re-examination criteria, includes: The test results with residual sustained-release interference labels are associated with the flushing procedure execution records by sample number. The adjusted tumor marker concentration, residual sustained-release interference labels, number of flushing times, flushing duration, and the results of the correction and re-examination criteria are integrated and written into the test evaluation record. Based on the detection and evaluation records, the adjusted tumor marker concentrations, residual sustained-release interference indicators, and correction and re-examination indications are displayed on the biochemical analyzer interface.
9. A blood sample test result evaluation and analysis system, characterized in that, The system includes: The sample risk level classification module is used to collect the total protein concentration of the preceding sample, detect the total protein content level through the built-in detection unit of the biochemical analyzer, and classify the risk level of the preceding sample according to the total protein content level. The flushing plan query module is used to query a pre-established flushing plan comparison table based on the risk level of the preceding sample, and extract the flushing execution plan corresponding to the risk level from the flushing plan comparison table; The flushing mode control module is used to identify the detection item type of the subsequent sample, analyze the combination relationship between the risk level of the preceding sample and the detection item type of the subsequent sample, and when the preceding sample is of high protein level and the subsequent sample is a tumor marker detection item, it is marked as a preceding high protein sample, the flushing execution plan is executed, and the flushing program execution record is recorded to obtain the ready state of the injection needle after cleaning. The sample injection and detection execution module is used to detect the original detection value of tumor markers in the subsequent sample based on the ready state of the cleaned injection needle, and simultaneously record the number of intervals between the subsequent sample and the preceding high-protein sample to obtain the initial tumor marker concentration and sample interval number of the subsequent sample. The concentration compensation module is used to query the residual interference coefficient based on the risk level of the preceding sample and the number of digits of the sample interval, and to compensate the initial tumor marker concentration based on the residual interference coefficient to obtain the adjusted tumor marker concentration. The false elevation assessment module is used to compare the adjusted tumor marker concentration with a preset false elevation identification threshold. When the false elevation identification threshold is exceeded, it is marked as a residual sustained-release interference indicator. At the same time, the adjusted tumor marker concentration is compared with a preset re-examination threshold to obtain the result of the correction re-examination indication determination. The results integration and presentation module is used to associate the detection results with the residual slow-release interference indicator with the flushing procedure execution record, and present the results on the biochemical analyzer display interface according to the correction and review criteria.